The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
The collaboration is focused on using Biognosys' HRM mass spec technology to facilitate Biodesix's companion diagnostic work.
The company posted second quarter revenues of $494.7 million, up from $481.8 million in Q2 2014 and beating the average Wall Street estimate of $481.7 million.
The five-year grant will support optimizing the use of polymyxin B to treat Gram-negative bacterial infections and identify protein biomarkers of drug-associated toxicity.
The researchers will use the expressed proteins to refine and optimize multiple-reaction monitoring assays that they will then apply to actual biological samples.
In Cell this week: map of human protein interactions, mutant phenotype variability in organisms of the same species from different genetic backgrounds, and more.
Critics call the Fred Hutchinson Cancer Research Center's Gary Gilliland's prediction of cancer cures within 10 years "out of touch with reality" and "irresponsible."
Ivan Oransky discusses the need for reproducibility research at The Conversation.
The San Diego Union-Tribune posts videos from Biocom's Speaker Series with Illumina's Jay Flatley, who discusses Roche's failed hostile takeover bid.